Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study

被引：0
|
作者：
Maspero, Jorge [1 ]
Kerstjens, Huib A. M. [2 ,3 ]
Chapman, Kenneth R. [4 ]
Van Zyl-Smit, Richard [5 ,6 ]
Tanase, Ana-Maria [7 ]
Lawrence, David [8 ]
Pethe, Abhijit [8 ]
Mezzi, Karen [7 ]
D'Andrea, Peter [8 ]
机构：
[1] Fdn CIDEA, Allergy & Resp Res Unit, Buenos Aires, DF, Argentina
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands
[3] Groningen Res Inst Asthma & COPD, Groningen, Netherlands
[4] Univ Toronto, Div Resp Med, Dept Med, Toronto, ON, Canada
[5] Univ Cape Town, Div Pulmonol, Cape Town, South Africa
[6] Univ Cape Town, UCT Lung Inst, Cape Town, South Africa
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Treatments; Asthma; -; management;
D O I：
10.1183/13993003.congress-2021.PA3391
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA3391
引用
收藏
页数：3
相关论文
共 13 条
  • [1] Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
    Kerstjens, Huib A. M.
    Maspero, Jorge F.
    Chapman, Kenneth R.
    Van Zyl-Smit, Richard
    Tanase, Ana-Maria
    Lawrence, David
    Pethe, Abhijit
    Mezzi, Karen
    D'Andrea, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [2] Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study
    Chapman, Kenneth R.
    Van Zyl-Smit, Richard N.
    Kerstjens, Huib A. M.
    Maspero, Jorge F.
    Hosoe, Motoi
    Tanase, Ana-Maria
    Pethe, Abhijit
    D'Andrea, Peter
    Brittain, Dominic
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Efficacy of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of salmeterol/ fluticasone (SAL/FLU) & tiotropium (TIO) in patients with uncontrolled asthma on prior LABA/ICS high-dose (GINA step 5): Results from ARGON study
    Gessner, C.
    Lawrence, D.
    Mezzi, K.
    Brittain, D.
    Smit, R. Van-Zyl
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [4] Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
    Kostikas, Konstantinos
    Kerstjens, Huib A. M.
    Maspero, Jorge F.
    Chapman, Kenneth R.
    Van Zyl-Smit, Richard N.
    Hosoe, Motoi
    Tanase, Ana-Maria
    Pethe, Abhijit
    Kottakis, Ioannis
    D'Andrea, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [5] Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study
    Kerstjens, Huib A. M.
    Van Zyl-Smit, Richard
    Chapman, Kenneth
    Maspero, Jorge
    Hosoe, Motoi
    Tanase, Ana-Maria
    Lawrence, David
    Pethe, Abhijit
    Shu, Xu
    Mezzi, Karen
    D'Andrea, Peter
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [6] Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study
    Chapman, Kenneth R.
    Kostikas, Konstantinos
    Kerstjens, Huib A. M.
    D'Andrea, Peter
    Hosoe, Motoi
    Jain, Devendra
    Pethe, Abhijit
    Tanase, Ana-Maria
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [7] Efficacy of once-daily medium- or high-dose mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus twice- daily high-dose fluticasone/salmeterol (FLU/SAL) to control nocturnal symptoms in patients (pts) with inadequately controlled asthma
    Chapman, K. R.
    Smit, R. Van-Zyl
    Mezzi, K.
    Brittain, D.
    Kerstjens, H. A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [8] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) REDUCES THE RISK OF EXACERBATIONS VERSUS SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS IRRESPECTIVE OF PRIOR ICS/LABA/LAMA THERAPY: THE FLAME STUDY
    Wedzicha, Jadwiga A.
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 84 - 84
  • [9] Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
    Gessner, Christian
    Kornmann, Oliver
    Maspero, Jorge
    Van Zyl-Smit, Richard
    Kruell, Matthias
    Sojo, Agustin
    Salina, Anna
    Gupta, Pritam
    Conde, Lorena Garcia
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [10] LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
    Wedzicha, Jadwiga
    Mezzi, Karen
    Ayers, Tim
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12